Exploring potential ways to evolve hemophilia treatment
Learn how Pfizer is researching potential alternate approaches to hemophilia treatment.
As part of our longstanding commitment to the hemophilia community, Pfizer continues to develop potential treatments that we hope will help people living with this bleeding disorder. Our current research is focused on gene therapy as well as a study medicine that aims to reduce the burden associated with traditional factor replacement products.
We’re studying investigational gene therapies that are designed to help people with hemophilia A or B produce clotting factor. (Learn about gene therapy below.) In partnership with everyone who enrolls in our clinical trials, we are evaluating whether this helps prevent bleeding episodes or reduce how often replacement factor infusions are needed.
We’re also committed to exploring a once-weekly shot under the skin for people with severe hemophilia A or B. This study medicine is a non-factor hemophilia treatment option that works for people without or with inhibitors. It is designed to reduce how often the shots are required, compared with existing factor replacement.
If you or a loved one are considering taking part in a hemophilia clinical trial, find more information below.